Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ProQR Therapeutics N.V.
  6. Summary
    PRQR   NL0010872495

PROQR THERAPEUTICS N.V.

(PRQR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
7.19(c) 7.59(c) 6.86(c) 6.74(c) 7.06(c) Last
215 205 1 685 268 992 565 356 259 249 012 Volume
-0.28% +5.56% -9.62% -1.75% +4.75% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,74 M - -
Net income 2021 -67,4 M - -
Net cash position 2021 136 M - -
P/E ratio 2021 -5,93x
Yield 2021 -
Sales 2022 9,10 M - -
Net income 2022 -88,9 M - -
Net cash position 2022 67,7 M - -
P/E ratio 2022 -5,05x
Yield 2022 -
Capitalization 467 M 467 M -
EV / Sales 2021 445x
EV / Sales 2022 43,9x
Nbr of Employees -
Free-Float 97,7%
More Financials
Company
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic... 
Read more
More about the company
Ratings of ProQR Therapeutics N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROQR THERAPEUTICS N.V.
06/17PROQR THERAPEUTICS N  : Plain-language summary of Retina Leroy BP, et al. paper
PU
06/10ProQR to Present at Upcoming JMP Securities Life Sciences Conference
GL
05/07PROQR THERAPEUTICS N  : ARVO Russell SR et al., Safety and efficacy of sepofarse..
PU
05/06PROQR : Q1 Earnings Snapshot
AQ
05/06ProQR Announces First Quarter 2021 Operating and Financial Results
GL
05/04PROQR THERAPEUTICS N  : Yarrow Biotechnology Sign License, Discovery Collaborati..
MT
05/04ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated..
GL
05/03PROQR THERAPEUTICS N  : Stifel Starts ProQR Therapeutics at Buy with $20 Price T..
MT
04/23ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial ..
GL
04/22ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
GL
04/20ProQR Announces Annual Meeting of Shareholders
GL
04/13PROQR THERAPEUTICS N  : Publishes Sepofarsen Trial Data in Scientific Journal Na..
MT
04/13ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congen..
GL
04/05ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares wi..
GL
04/02ProQR Announces Virtual Presentation at American Association for Pediatric Op..
GL
More news
News in other languages on PROQR THERAPEUTICS N.V.

- No features available -

More news
Analyst Recommendations on PROQR THERAPEUTICS N.V.
More recommendations
Chart PROQR THERAPEUTICS N.V.
Duration : Period :
ProQR Therapeutics N.V. Technical Analysis Chart | PRQR | NL0010872495 | MarketScreener
Technical analysis trends PROQR THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 7,06 $
Average target price 26,00 $
Spread / Average Target 268%
EPS Revisions
Managers and Directors
NameTitle
Daniel Anton de Boer Chief Executive Officer
Smital Shah Chief Financial & Business Officer
Domenico Valerio Chairman-Supervisory Board
Aniz Girach Chief Medical Officer
Jennifer Pluim Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PROQR THERAPEUTICS N.V.60.48%446
GILEAD SCIENCES, INC.14.40%84 093
WUXI APPTEC CO., LTD.36.51%68 536
BIONTECH SE181.53%57 117
REGENERON PHARMACEUTICALS9.66%55 301
VERTEX PHARMACEUTICALS-20.66%48 892